Interactive Decision Support Tool


Program Content


  • HER2 MBC Treatment Tool
    Interactive Decision Support Tool: HER2-Positive Metastatic Breast Cancer Expert Guidance
    Congratulations: You achieved a completion on 04/09/2022

    Released: November 23, 2022

    Expires: November 22, 2023


cover img faculity

Aditya Bardia, MD, MPH, FASCO

Professor of Medicine
Geffen School of Medicine at UCLA
Director, Breast Oncology Program
Assistant Chief (Translational Research)
Division of Medical Oncology
Director of Translational Research Integration
UCLA Health Jonsson Comprehensive Cancer Center
Los Angeles, California

cover img faculity

Sara A. Hurvitz, MD

Professor of Medicine
Breast Cancer Clinical Trials Program
Division of Hematology/Oncology
David Geffen School of Medicine
Medical Director
Clinical Research Unit
Jonsson Comprehensive Cancer Center
University of California, Los Angeles
Los Angeles, California

cover img faculity

Komal Jhaveri, MD, FACP

Associate Attending
Breast Medicine Service and Early Drug Development Service
Section Head, Endocrine Therapy Research Program
Clinical Director, Early Drug Development Service
Department of Medicine
Associate Professor of Medicine
Weill Cornell Medical College
New York, New York

cover img faculity

Heather McArthur, MD, MPH

Associate Professor
Department of Internal Medicine
Clinical Director, Breast Cancer Program
Komen Distinguished Chair in Clinical Breast Cancer Research
UT Southwestern Medical Center
Dallas, Texas

cover img faculity

Sara M. Tolaney, MD, MPH

Assistant Professor of Medicine
Harvard Medical School
Associate Director
Susan F. Smith Center for Women’s Cancers
Clinical Trials, Breast Oncology
Breast Immunotherapy Clinical Research
Dana-Farber Cancer Institute
Boston, Massachusetts

Provided by

ProCE Banner



Daiichi Sankyo, Inc.

Puma Biotechnology, Inc.

Seagen Inc.


Smart Patients

ProCE Banner